PHILADELPHIA (AP) — A U.S. health panel says it’s time to resume use of Johnson & Johnson’s COVID-19 vaccine, despite a very rare risk of blood clots. Out of nearly 8 million people vaccinated before the U.S. suspended J&J’s shot, health officials uncovered 15 cases of a highly unusual kind of blood clot, three of them fatal.

All were women, most younger than 50.

READ MORE: Police Searching For Dirt Bike Rider Wanted In Hit-And-Run Crash In North Philadelphia

But advisers to the Centers for Disease Control and Prevention said Friday the vaccine’s benefits outweigh that serious but small risk — especially against a virus that’s still infecting tens of thousands of Americans every day.

READ MORE: Police: 16-Year-Old Boy Critically Wounded After Being Shot 7 Times in West Philadelphia

The government will rapidly weigh that recommendation in deciding next steps.

MORE NEWS: Crime Again On Top Of Philadelphia Voters' Minds After 2 Pregnant Women Shot Within Days Of Each Other

(Copyright 2021 by The Associated Press. All Rights Reserved.)